Leukemia, Lymphoma & Myeloma: Patient Education

Overview

Leukemia, lymphoma and myeloma are malignancies of the blood.

Leukemia is cancer of your white blood cells. There are four primary types of leukemia and numerous subtypes.

  • Acute lymphocytic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myeloid leukemia (CML)

Lymphoma is cancer of your lymph system. There are two primary types of lymphoma and numerous subtypes.

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma

Myeloma is cancer of your antibody-making plasma cells. If myeloma strikes in more than one location, it’s called multiple myeloma. There are two primary types of myeloma.

  • Symptomatic
  • Asymptomatic

Each of the blood cancers is treated differently. In many cases, the subtypes within the different blood cancers require different treatments.

For more information, please select from the blood malignancies above.

Back to Top

We Lead the Way in Developing New Treatments

New treatments. Fresh hope.

Members of your Scott & White Leukemia, Lymphoma & Myeloma Team are actively involved in developing new and effective treatments to bring your leukemia, lymphoma or myeloma under control and bring hope for cure.

As part of our Scott & White Cancer Research Institute (CRI), your physicians understand the necessity of making innovative discoveries of fresh approaches to therapies and medications—and speeding their development for your use.

Our Scott & White Cancer Research Institute Team is comprised of:

  • Members of your Leukemia, Lymphoma & Myeloma Team
  • Research scientists
  • Pharmacologists
  • Nurses
  • Microbiologists
  • Biotechnologists

The CRI Team has developed several new cancer drugs, which they supply to other cancer centers in the United States and Canada.

Many more groundbreaking therapies are in the clinical-trial stage. Great progress is underway in securing effective treatments for leukemia, lymphoma and myeloma.

Please discuss with your physician whether you are a candidate for one of our clinical trials for one of these new agents.

Back to Top


Print
Text Size
A
A
A